Abstract: A filter holder comprises: a plurality of filter frames disposed such that at least some thereof are adjacent to each other; and a folding member which supports filter frames, from among the plurality of filter frames, adjacent to each other so as to be rotatable with respect to each other. The folding member comprises: a folding part which has a predetermined thickness and is flexible so as to be foldable by means of rotation of the adjacent filter frames adjacent with respect to each other; and a plurality of edge parts which are connected to the respective sides of the folding part with the folding portion therebetween and rotate together with the adjacent filter frames, and wherein when viewed from a cross-section of the folding member, the edge parts may have a greater thickness than the folding part.

Abstract: A composition for strengthening, developing, differentiating, or regenerating muscle, or preventing, ameliorating, or treating muscle loss or muscle fatigue includes a Schizonepeta tenuifolia extract as an effective component. The Schizonepeta tenuifolia extract as an effective component has the effects of restoring the viability of muscle cells, increasing the endurance time on the rotarod performance test, i.e., the holding time without falling off from the rod, compared to the control group, reducing the content of LDH, AST, and ALT in blood, increasing the grip strength, enhancing the expression amount of energy metabolism-related genes in muscle tissues, increasing the density of muscle fibers in muscle tissues, inducing a change in the fibroblast arrangement to have a well-organized structure, and reducing the expression of MuRF1 in muscle tissues, as compared to the control group.

Abstract: Proposed are an unsupported metallic catalyst for a selective ring-opening (SRO) reaction and a method of using the same catalyst, wherein the catalyst contains nickel (Ni), molybdenum (Mo), and tungsten (W).

Abstract: An air filter comprises: a first filter frame in which a plurality of first chambers are formed; a second filter frame in which a plurality of second chambers are formed and which is arranged at the rear of the first filter frame; and a filter material which is accommodated in the plurality of first chambers and the plurality of second chambers to filter air, wherein the first filter frame and the second filter frame are arranged so that, when seen from the front, the center of each of the plurality of second chambers is out of line with the center of each of the plurality of first chambers, in the vertical direction.

Abstract: A mobile robot platooning system includes a plurality of mobile robots operated for transfer of objects in a factory, and a central server connected to the plurality of mobile robots through wireless communication, and configured to set a path of the plurality of mobile robots to control autonomous driving of the mobile robots, wherein the central server is configured to group a platoon of the mobile robots required for processing a work, dispose the platoon of the mobile robots into a predetermined platoon form, collect state information of the platoon of the mobile robots, and control the platoon of the mobile robots to move in a synchronized form based on the state information.

Abstract: A self-healing alloy contains 5 to 11% by weight of molybdenum (Mo), iron (Fe) as a remainder, and unavoidable impurities. A method for manufacturing the self-healing alloy includes heat treating the alloy or preparing an alloy raw material powder and sintering, homogenizing, and cooling the alloy raw material powder.

Abstract: A method and an electronic device for translating a speech signal between a first language and a second language with minimized translation delay by translating fewer than all words of the speech signal according to a level of understanding of the second language by a user that receives the translation.

Abstract: A food composition for preventing or improving sleep disorders caused by caffeine containing a citrus rind extract is provided. The citrus is at least one selected from the group consisting of clementine, kumquat, mandarin, tangerine, sweetie, citron, citrus sudachi, cheonhyehyang, calamansi, pomelo, hanrabong, orange, lemon, grapefruit, lime, and yuja.The extract is extracted with water, alcohol, ethyl acetate, acetone, nucleic acid, dichloromethane, or a mixed solvent thereof.

Abstract: The present invention relates to a method for purifying darbepoetin alfa by selectively separating only a structural isoform having a high content of sialic acid from a mixture of structural isoforms of darbepoetin alfa having various contents of sialic acid. Since the method of the present invention is a novel method for purifying darbepoetin alfa which can be conveniently and simply produced, it is possible to remarkably increase productivity due to process efficiency improvement, as well as to yield high purity darbepoetin alfa when mass-producing darbepoetin alfa according to the present invention.

Abstract: The present invention provides a pharmaceutical composition with improved stability, comprising a fusion protein comprising Factor VII (FVII) and transferrin, as an active ingredient, wherein the transferrin is linked to the C-terminus of the FVII; and trehalose or glycine as a bulking agent. The composition can store FVII and a variant thereof stably at room temperature for a long period of time. Thus it can be used as a useful therapeutic agent for patients suffering from hemophilia or congenital FVII deficiency.

Abstract: The present invention relates to a long-acting human growth hormone NexP-hGH protein and its production method. More specifically, it relates to a specific isoform of long-acting human growth hormone NexP-hGH protein in which human growth hormone is fused with a highly glycosylated alpha-1 antitrypsin mutant whereby long-acting properties in vivo are increased.

Abstract: The present invention relates to a method for purifying darbepoetin alfa by selectively separating only a structural isoform having a high content of sialic acid from a mixture of structural isoforms of darbepoetin alfa having various contents of sialic acid. Since the method of the present invention is a novel method for purifying darbepoetin alfa which can be conveniently and simply produced, it is possible to remarkably increase productivity due to process efficiency improvement, as well as to yield high purity darbepoetin alfa when mass-producing darbepoetin alfa according to the present invention.

Abstract: The present invention relates to a method for preparing polymeric microspheres to improve the drug encapsulating efficiency and, more specifically, to a method for preparing polymeric microspheres, the method comprising the steps of: preparing an internal water phase (w1) and an oil phase (0); mixing the internal water phase and the oil phase to prepare a W1/0 emulsion, followed by cooling; mixing the W1/0 emulsion with an external water phase (W2) to prepare a W1/0/W2 emulsion; and drying the prepared W1/0/W2 emulsion, followed by collection. The method of the present invention can increase the drug encapsulating efficiency and manufacture polymeric microspheres having high drug contents through a procedure of maintaining the step of solidifying the oil phase at a particular temperature for a particular period of time, and thus the method of the present invention is effective in the preparation of sustained release-type drugs.

Abstract: The present invention provides a pharmaceutical composition with improved stability, comprising a fusion protein comprising factor VII(FVII) and transferrin, as an active ingredient, wherein the transferrin is linked to the C-terminus of the FVII; and trehalose or glycine as a bulking agent. The composition can store FVII and a variant thereof stably at room temperature for a long period of time. Thus it can be used as a useful therapeutic agent for patients suffering from hemophilia or congenital FVII deficiency.

Abstract: Provided are picolinamide and pyrimidine-4-carboxamide compounds, a method for preparing the same, a pharmaceutical composition containing the same, and a medical use using the compound as an agent for preventing, regulating, and treating diseases related to regulation of glucocorticoids by using selective inhibitory activity of the compound for an 11?-HSD1 enzyme. The picolinamide and pyrimidine-4-carboxamide compounds of the present invention are selective inhibitors of human-derived 11?-HSD1 enzymes, and are useful in an agent for preventing, regulating, and treating diseases related to glucocorticoid regulation in which human-derived 11?-HSD1 enzymes are involved, for example, metabolic syndromes such as, type 1 and type 2 diabetes, diabetes later complications, latent autoimmune diabetes adult (LADA), insulin tolerance syndromes, obesity, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), damaged glucose tolerance, dyslipidemia, atherosclerosis, hypertension, etc.

Abstract: The present invention relates to a long-acting human growth hormone NexP-hGH protein and its production method. More specifically, it relates to a specific isoform of long-acting human growth hormone NexP-hGH protein in which human growth hormone is fused with a highly glycosylated alpha-1 antitrypsin mutant whereby long-acting properties in vivo are increased.

Abstract: The present invention relates to a stable pharmaceutical composition for injection containing docetaxel and a method of preparing the same. More particularly, the present invention relates to a pharmaceutical composition for injection containing docetaxel having better storage stability than conventional medications, which is prepared by dissolving docetaxel, a water-insoluble compound, in distilled water after mixing it with cyclodextrin (CD) and a water-soluble polymer such as hydroxypropyl methylcellulose (HPMC), polyethylene glycol (PEG) or polyvinylpyrrolidone (PVP) and lyophilizing the mixture, and a method of preparing the same.

Abstract: Provided are picolinamide and pyrimidine-4-carboxamide compounds, a method for preparing the same, a pharmaceutical composition containing the same, and a medical use using the compound as an agent for preventing, regulating, and treating diseases related to regulation of glucocorticoids by using selective inhibitory activity of the compound for an 11?-HSD1 enzyme. The picolinamide and pyrimidine-4-carboxamide compounds of the present invention are selective inhibitors of human-derived 11?-HSD1 enzymes, and are useful in an agent for preventing, regulating, and treating diseases related to glucocorticoid regulation in which human-derived 11?-HSD1 enzymes are involved, for example, metabolic syndromes such as, type 1 and type 2 diabetes, diabetes later complications, latent autoimmune diabetes adult (LADA), insulin tolerance syndromes, obesity, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), damaged glucose tolerance, dyslipidemia, atherosclerosis, hypertension, etc.

Abstract: The present invention relates to a sibutramine-containing inclusion complex having superior storage stability, and particularly to a pharmaceutically stable inclusion complex suitable for the drug formulation, which prepared by reacting a sibutramine (N,N-dimethyl-1-[1-(4-chlorophenyl)-cyclobutyl]-3-methylbutylamine) of Formula 1 and beta-cyclodextrin in a predetermined ratio, its preparation method and a pharmaceutical composition comprising the same.

Abstract: The present invention relates to salts of a pyrrolopyrimidinone derivative having superior PDE-5 inhibition activity and a process for preparing the same. More particularly, the present invention relates to a crystalline acid addition salt prepared by reacting a pyrrolopyrimidinone derivative with an acid selected from gentisic acid, maleic acid, citric acid, fumaric acid and tartaric acid. With no hygroscopic property and superior long-term storage stability, photostability and thermal stability, the salts of the pyrrolopyrimidinone derivative are appropriate to be prepared into medications and, with superior PDE-5 inhibition activity, are useful for the treatment and prevention of erectile dysfunction, pulmonary arterial hypertension, chronic obstructive pulmonary disease, benign prostatic hypertrophy and lower urinary tract diseases.